Farletuzumab (MORAb-003) is a humanized monoclonal antibody[1] of IgG1/κ[2] which is being investigated for the treatment of ovarian cancer.

[3][4] This drug was developed by Morphotek, Inc.

It is targeted at folate receptor alpha (FRα) which is overexpressed in some cancers such as epithelial ovarian cancer (EOC) and non-small-cell lung carcinoma.

[2] Farletuzumab uses the following mechanisms of action:[2] Common adverse effects include hypersensitivity reactions, fever, chills, headache, fatigue, and diarrhea.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.